MMSI Stock Charts

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2011-12-31	2011-09-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2004-03-31


current assets:
cash and cash equivalents	392,457,000	341,819,000	395,529,000	376,715,000	523,128,000	636,658,000	581,921,000	587,036,000	58,673,000	72,084,000	57,945,000	58,408,000	51,481,000	63,003,000	53,875,000	67,750,000	68,904,000	69,672,000	58,519,000	56,916,000	44,551,000	49,702,000	50,080,000	44,320,000	37,315,000	35,182,000	49,522,000					32,336,000			26,464,000			10,487,000														5,819,000	3,465,000	5,298,000	4,254,000	5,992,000		5,763,000	4,873,000	16,430,000	31,081,000	26,756,000	23,757,000		12,199,000	9,281,000	9,645,000		7,005,000	7,644,000	9,014,000	11,976,000	18,835,000	28,617,000	34,434,000	35,865,142
trade receivables — net of allowance for credit losses — 2025 — 10,113 and 2024 — 9,729	210,292,000
other receivables	19,062,000	14,292,000	17,116,000	16,588,000	15,325,000	10,612,000	10,980,000	10,517,000	13,576,000	12,634,000	14,559,000	12,992,000	10,827,000	10,627,000	11,748,000	17,763,000	10,659,000	8,376,000	8,719,000	7,774,000	8,073,000	8,214,000	9,246,000	10,016,000	11,751,000	11,520,000	10,694,000	-2,754,000	255,000	966,000	898,000	9,429,000	-503,000	-168,000	4,902,000	1,146,000	3,385,000	4,742,000	1,367,000	387,000	-735,000	-3,042,000	-885,000	-753,000	439,000	-609,000	-463,000	-586,000	-760,000	-490,000	-245,000	1,442,000	1,267,000	1,641,000	447,000	644,000		465,000	460,000	711,000	706,000	800,000	929,000		882,000	734,000	457,000		293,000	553,000	252,000	270,000	253,000
inventories	326,550,000	323,309,000	317,936,000	306,063,000	310,527,000	298,224,000	302,733,000	303,871,000	303,923,000	305,943,000	289,581,000	265,991,000	246,660,000	233,154,000	231,451,000	221,922,000	208,081,000	194,524,000	200,308,000	198,019,000	209,109,000	221,417,000	227,776,000	225,698,000	216,766,000	202,994,000	198,922,000	-28,172,000	-19,375,000	-7,189,000	-5,388,000	155,288,000	-9,922,000	-2,160,000	134,310,000	-3,656,000	220,000	109,858,000	-2,272,000	-13,113,000	3,518,000	-9,396,000	-10,553,000	-4,094,000	-2,352,000	2,334,000	3,039,000	2,149,000	-8,965,000	-8,884,000	-9,314,000	66,557,000	60,353,000	58,356,000	47,219,000	46,818,000		48,036,000	46,308,000	42,953,000	38,399,000	36,274,000	34,623,000	5,056,000	36,794,000	38,373,000	38,960,000		37,752,000	35,756,000	33,607,000	29,699,000	26,715,000	24,493,000	23,496,000	22,888,456
prepaid expenses and other current assets	31,369,000	30,162,000	25,007,000	28,544,000	27,105,000	26,179,000	24,437,000	24,286,000	27,954,000	24,971,000	19,961,000	22,324,000	27,388,000	23,050,000	19,809,000	16,149,000	18,778,000	16,541,000	13,617,000	13,120,000	15,579,000	13,860,000	16,284,000	12,497,000	17,610,000			-2,000,000	-2,719,000	-3,105,000	-1,223,000
prepaid income taxes	3,651,000	3,543,000	3,417,000	3,286,000	4,216,000	4,123,000	4,088,000	4,016,000	3,936,000	3,920,000	3,920,000	3,913,000	3,515,000	3,532,000	3,547,000	3,550,000	3,679,000	3,683,000	3,680,000	3,688,000	3,545,000	3,493,000	3,486,000	3,491,000	3,611,000	3,625,000	3,620,000	-444,000	-120,000	-100,000	-72,000	3,225,000	-231,000	-92,000	2,604,000	404,000	-63,000	3,044,000	-38,000	-1,788,000	52,000	-41,000	33,000	3,000		18,000	8,000	17,000	-367,000	2,000	-431,000
income tax refund receivables	2,152,000	5,785,000	80,000	2,335,000	8,185,000	4,335,000	453,000	859,000	9,432,000	4,365,000	1,069,000	779,000	4,164,000	464,000	1,803,000	2,777,000	2,561,000	3,543,000	3,331,000	3,549,000	11,812,000	10,467,000	5,586,000	3,151,000	9,566,000	4,876,000	1,317,000	232,000	134,000	-1,146,000	-205,000	1,211,000	280,000	294,000	680,000	406,000	514,000	43,000	424,000	-784,000	-539,000	11,000	10,000	24,000	192,000	1,267,000																													2,000
total current assets	985,533,000	923,072,000	958,635,000	923,774,000	1,078,317,000	1,162,546,000	1,105,275,000	1,108,470,000	585,318,000	594,907,000	557,217,000	529,084,000	499,863,000	492,631,000	478,092,000	482,212,000	463,442,000	449,782,000	438,488,000	429,707,000	434,626,000	445,945,000	462,508,000	454,538,000	441,302,000	426,946,000	421,783,000					316,121,000			272,151,000			219,977,000														123,956,000	115,388,000	112,451,000	95,588,000	94,145,000		91,529,000	87,625,000	94,592,000	102,201,000	93,264,000	88,438,000		76,409,000	75,443,000	76,716,000		70,146,000	69,032,000	66,793,000	65,112,000	68,400,000	74,636,000	76,375,000	80,798,942
property and equipment:
land and land improvements	30,457,000	30,467,000	27,058,000	25,846,000	26,108,000	25,952,000	25,982,000	26,017,000	26,017,000	26,017,000	26,017,000	25,940,000	25,699,000	25,163,000	25,380,000	25,287,000	25,394,000	28,180,000	28,087,000	28,400,000	28,090,000	27,815,000	27,695,000	27,554,000	27,412,000	27,651,000	26,764,000					19,877,000			19,454,000			19,400,000														15,752,000	12,579,000	10,931,000	10,932,000	10,316,000		9,776,000	7,992,000	7,992,000	7,977,000	7,977,000	7,977,000		8,107,000	8,026,000	7,958,000		7,877,000	7,885,000	6,235,000	6,166,000	5,669,000	5,667,000
buildings	198,563,000	198,505,000	193,561,000	192,296,000	192,323,000	191,030,000	191,218,000	191,491,000	190,825,000	189,900,000	189,947,000	189,148,000	186,976,000	188,550,000	189,773,000	190,044,000	190,335,000	188,089,000	187,774,000	188,878,000	182,914,000	181,749,000	153,896,000	153,863,000	152,782,000	153,502,000	152,974,000					147,356,000			141,065,000			139,140,000
manufacturing equipment	357,135,000	353,119,000	345,272,000	340,864,000	334,787,000	330,290,000	327,628,000	316,930,000	313,600,000	306,925,000	303,547,000	299,089,000	290,306,000	286,257,000	283,802,000	277,976,000	275,155,000	272,084,000	270,754,000	268,894,000	266,755,000	257,493,000	247,878,000	244,368,000	234,121,000	230,315,000	225,402,000					197,651,000			186,323,000			166,034,000														101,660,000	94,176,000	85,572,000	83,997,000	78,965,000		75,019,000	73,640,000	70,482,000	66,797,000	65,708,000	64,487,000		61,531,000	55,656,000	55,008,000		53,266,000	50,218,000	48,164,000	42,409,000	34,243,000	33,253,000	31,155,000	30,646,287
furniture and fixtures	64,115,000	64,102,000	62,673,000	61,321,000	66,593,000	64,755,000	63,790,000	63,044,000	66,451,000	66,046,000	64,762,000	61,128,000	63,380,000	62,620,000	61,877,000	61,446,000	62,445,000	62,142,000	61,422,000	61,586,000	61,830,000	60,358,000	58,955,000	57,623,000	59,487,000	57,565,000	55,378,000					49,528,000			45,302,000			42,478,000														21,302,000	19,091,000	17,979,000	17,215,000	16,390,000		15,550,000	15,113,000	14,336,000	18,196,000	17,811,000	17,322,000		17,456,000	17,007,000	16,585,000		17,164,000	16,941,000	16,367,000	15,262,000	13,776,000	13,190,000	12,620,000	12,430,876
leasehold improvements	62,067,000	60,649,000	59,447,000	58,770,000	59,005,000	58,595,000	53,772,000	53,638,000	53,208,000	52,604,000	50,826,000	49,673,000	49,962,000	48,813,000	48,060,000	46,341,000	45,750,000	47,217,000	48,319,000	48,800,000	48,549,000	44,952,000	43,950,000	43,311,000	36,992,000	34,518,000	34,221,000					31,161,000			30,633,000			29,267,000														12,632,000	12,360,000	12,034,000	11,870,000	10,487,000		10,122,000	9,906,000	9,881,000	9,926,000	9,941,000	9,902,000		10,039,000	7,739,000	7,726,000		7,654,000	6,630,000	6,694,000	4,117,000	4,115,000	4,107,000	4,098,000	4,715,444
construction-in-progress	83,417,000	74,850,000	63,722,000	58,673,000	66,699,000	61,060,000	58,296,000	61,439,000	60,492,000	62,374,000	63,786,000	61,269,000	59,783,000	54,409,000	50,870,000	51,182,000	51,756,000	48,608,000	47,735,000	46,889,000	50,251,000	59,523,000	91,802,000	83,685,000	85,703,000	69,370,000	61,304,000					32,896,000			29,259,000			31,795,000														41,517,000	21,903,000	15,964,000	11,609,000	14,371,000		11,476,000	9,219,000	9,103,000	7,932,000	6,692,000	10,619,000		8,565,000	14,315,000	11,148,000		7,874,000	8,431,000	8,270,000	13,454,000	29,464,000	21,600,000	20,859,000	12,620,085
total property and equipment	795,754,000	781,692,000	751,733,000	737,770,000	745,515,000	731,682,000	720,686,000	712,559,000	710,593,000	703,866,000	698,885,000	686,247,000	676,106,000	665,812,000	659,762,000	652,276,000	650,835,000	646,320,000	644,091,000	643,447,000	638,389,000	631,890,000	624,176,000	610,404,000	596,497,000	572,921,000	556,043,000					478,469,000			452,036,000			428,114,000
less accumulated depreciation	-377,750,000	-371,707,000	-361,409,000	-351,605,000	-355,862,000	-345,743,000	-337,025,000	-329,036,000	-327,267,000	-319,504,000	-311,435,000	-303,271,000	-299,950,000	-294,361,000	-287,853,000	-280,618,000	-277,379,000	-272,519,000	-265,914,000	-260,719,000	-254,585,000	-248,261,000	-239,316,000	-231,619,000	-229,596,000	-222,402,000	-215,279,000					-185,649,000			-168,652,000			-151,628,000														-81,412,000
property and equipment — net	418,004,000	409,985,000	390,324,000	386,165,000	389,653,000	385,939,000	383,661,000	383,523,000	383,326,000	384,362,000	387,450,000	382,976,000	376,156,000	371,451,000	371,909,000	371,658,000	373,456,000	373,801,000	378,177,000	382,728,000	383,804,000	383,629,000	384,860,000	378,785,000	366,901,000	350,519,000	340,764,000					292,820,000			283,384,000			276,486,000
other assets:
intangible assets:
developed technology — net of accumulated amortization — 2025 — 433,630 and 2024 — 377,993	468,819,000
other — net of accumulated amortization — 2025 — 93,600 and 2024 — 85,343	69,581,000
goodwill	507,427,000	504,555,000	464,360,000	463,511,000	399,448,000	381,433,000	381,539,000	382,240,000	381,052,000	381,767,000	360,291,000	359,821,000	358,056,000	359,692,000	361,456,000	361,741,000	362,000,000	362,810,000	362,500,000	363,533,000	353,622,000	353,093,000	352,242,000	353,193,000	352,158,000	352,133,000	334,951,000					238,147,000			219,911,000			187,034,000														61,144,000	58,659,000	54,738,000	33,002,000	33,002,000		32,849,000	32,567,000	21,124,000	11,680,000	11,680,000	11,651,000		9,099,000	9,068,000	9,684,000		8,090,000	7,579,000	6,470,000	5,750,000	5,738,000	5,717,000	4,765,000	4,764,596
deferred income tax assets	16,284,000	16,243,000	16,100,000	16,044,000	7,253,000	7,013,000	7,072,000	7,288,000	6,438,000	6,492,000	6,665,000	6,599,000	5,467,000	5,861,000	6,179,000	6,080,000	4,581,000	4,614,000	4,529,000	4,597,000	3,857,000	3,748,000	3,716,000	3,788,000	2,944,000	3,038,000	3,083,000											7,017,000														4,591,000	4,651,000	5,005,000	3,289,000	3,287,000		2,783,000	2,781,000	2,779,000	2,083,000	2,087,000	2,087,000		3,000	3,000	163,000		28,000	28,000	24,000	41,000	41,000	38,000		677,212
right-of-use operating lease assets	88,496,000	89,279,000	87,722,000	65,508,000	68,867,000	69,903,000	72,639,000	63,047,000	63,633,000	62,436,000	62,881,000	65,262,000	64,700,000	64,353,000	64,659,000	65,913,000	68,078,000	70,767,000	74,714,000	78,240,000	76,775,000	79,051,000	79,133,000	80,244,000	79,757,000	79,309,000	80,453,000
other assets	76,854,000	80,753,000	71,856,000	65,336,000	62,382,000	61,583,000	58,682,000	54,793,000	48,545,000	52,492,000	45,721,000	44,352,000	44,388,000	43,303,000	41,707,000	41,421,000	40,672,000	37,827,000	37,286,000	37,676,000	35,011,000	36,413,000	36,569,000	41,461,000	59,735,000	58,255,000	60,052,000	315,000	-1,370,000	-751,000	-491,000	35,040,000	-2,992,000	-1,500,000	29,098,000	-3,763,000	-1,591,000	14,770,000	109,000	-362,000	-602,000	-1,388,000	-1,128,000	-641,000	-847,000	-1,806,000	-813,000	-377,000	-1,178,000	-869,000	-283,000	8,053,000	9,664,000	7,265,000	6,592,000	6,483,000		3,030,000	2,730,000	2,181,000			2,911,000		2,844,000	2,921,000	2,830,000	102,000	2,659,000	2,424,000	2,552,000	2,254,000	1,980,000	1,856,000	1,441,000	1,268,768
total other assets	1,227,461,000	1,252,988,000	1,119,014,000	1,108,664,000	910,114,000	823,354,000	837,416,000	833,251,000	839,861,000	858,299,000	739,442,000	751,906,000	756,718,000	767,437,000	779,739,000	794,424,000	806,268,000	818,810,000	835,054,000	851,961,000	852,080,000	886,295,000	901,904,000	923,998,000	953,501,000	958,805,000	927,246,000					502,870,000			459,646,000			318,502,000														132,354,000	129,447,000	129,117,000	66,552,000	66,779,000		61,908,000	61,927,000	40,810,000	21,997,000	21,576,000	21,586,000		18,468,000	17,456,000	17,306,000		15,150,000	13,701,000	12,447,000	10,879,000	10,632,000	10,477,000	8,275,000	8,266,689
total assets	2,630,998,000	2,586,045,000	2,467,973,000	2,418,603,000	2,378,084,000	2,371,839,000	2,326,352,000	2,325,244,000	1,808,505,000	1,837,568,000	1,684,109,000	1,663,966,000	1,632,737,000	1,631,519,000	1,629,740,000	1,648,294,000	1,643,166,000	1,642,393,000	1,651,719,000	1,664,396,000	1,670,510,000	1,715,869,000	1,749,272,000	1,757,321,000																												418,833,000	380,417,000	364,042,000	280,212,000	277,136,000		264,631,000	257,065,000	241,150,000	227,922,000	217,435,000	210,759,000		193,165,000	190,596,000	189,443,000		177,107,000	172,720,000	166,074,000	158,981,000	153,417,000	146,340,000	128,994,000	125,498,399
see condensed notes to consolidated financial statements.
trade receivables — net of allowance for credit losses — 2025 — 10,108 and 2024 — 9,729		204,162,000
developed technology — net of accumulated amortization — 2025 — 414,713 and 2024 — 377,993		489,975,000
other — net of accumulated amortization — 2025 — 90,872 and 2024 — 85,343		72,183,000
trade receivables — net of allowance for credit losses — 2025 — 10,708 and 2024 — 9,729			199,550,000
developed technology — net of accumulated amortization — 2025 — 395,575 and 2024 — 377,993			414,348,000
other — net of accumulated amortization — 2025 — 87,986 and 2024 — 85,343			64,628,000
trade receivables — net of allowance for credit losses — 2024 — 9,729 and 2023 — 9,023				190,243,000
developed technology — net of accumulated amortization — 2024 — 377,993 and 2023 — 321,488				431,766,000
other — net of accumulated amortization — 2024 — 85,343 and 2023 — 76,887				66,499,000
see notes to consolidated financial statements.
trade receivables — net of allowance for credit losses — 2024 — 9,266 and 2023 — 9,023					189,831,000
developed technology — net of accumulated amortization — 2024 — 361,725 and 2023 — 321,488					322,325,000
other — net of accumulated amortization — 2024 — 82,979 and 2023 — 76,887					49,839,000
trade receivables — net of allowance for credit losses — 2024 — 9,276 and 2023 — 9,023						182,415,000
developed technology — net of accumulated amortization — 2024 — 346,763 and 2023 — 321,488						264,195,000
other — net of accumulated amortization — 2024 — 80,628 and 2023 — 76,887						39,227,000
trade receivables — net of allowance for credit losses — 2024 — 9,327 and 2023 — 9,023							180,663,000
developed technology — net of accumulated amortization — 2024 — 333,920 and 2023 — 321,488							277,085,000
other — net of accumulated amortization — 2024 — 78,771 and 2023 — 76,887							40,399,000
trade receivables — net of allowance for credit losses — 2023 — 9,023 and 2022 — 8,423								177,885,000
developed technology — net of accumulated amortization — 2023 — 321,488 and 2022 — 274,570								283,999,000
other — net of accumulated amortization — 2023 — 76,887 and 2022 — 69,780								41,884,000
trade receivables — net of allowance for credit losses — 2023 — 8,721 and 2022 — 8,423									167,824,000
developed technology — net of accumulated amortization — 2023 — 308,889 and 2022 — 274,570									296,349,000
other — net of accumulated amortization — 2023 — 76,909 and 2022 — 69,780									43,844,000
trade receivables — net of allowance for credit losses — 2023 — 8,652 and 2022 — 8,423										170,990,000
developed technology — net of accumulated amortization — 2023 — 296,131 and 2022 — 274,570										309,228,000
other — net of accumulated amortization — 2023 — 74,418 and 2022 — 69,780										45,884,000
trade receivables — net of allowance for credit losses — 2023 — 8,248 and 2022 — 8,423											170,182,000
developed technology — net of accumulated amortization — 2023 — 285,008 and 2022 — 274,570											227,203,000
other — net of accumulated amortization — 2023 — 71,742 and 2022 — 69,780											36,681,000
trade receivables — net of allowance for credit losses — 2022 — 8,423 and 2021 — 6,767												164,677,000
developed technology — net of accumulated amortization — 2022 — 274,570 and 2021 — 234,016												237,522,000
other — net of accumulated amortization — 2022 — 69,780 and 2021 — 65,053												38,350,000
trade receivables — net of allowance for credit losses — 2022 — 8,018 and 2021 — 6,767													155,828,000
developed technology — net of accumulated amortization — 2022 — 263,990 and 2021 — 234,016													245,282,000
other — net of accumulated amortization — 2022 — 68,308 and 2021 — 65,053													38,825,000
trade receivables — net of allowance for credit losses — 2022 — 7,738 and 2021 — 6,767														158,801,000
developed technology — net of accumulated amortization — 2022 — 254,031 and 2021 — 234,016														254,557,000
other — net of accumulated amortization — 2022 — 66,591 and 2021 — 65,053														39,671,000
trade receivables — net of allowance for credit losses — 2022 — 7,568 and 2021 — 6,767															155,859,000
developed technology — net of accumulated amortization — 2022 — 244,017 and 2021 — 234,016															264,839,000
other — net of accumulated amortization — 2022 — 66,924 and 2021 — 65,053															40,899,000
trade receivables — net of allowance for credit losses — 2021 — 6,767 and 2020 — 5,313																152,301,000
developed technology — net of accumulated amortization — 2021 — 234,016 and 2020 — 193,164																276,833,000
other — net of accumulated amortization — 2021 — 65,053 and 2020 — 56,943																42,436,000
trade receivables — net of allowance for credit losses — 2021 — 6,444 and 2020 — 5,313																	150,780,000
developed technology — net of accumulated amortization —2021 — 223,814 and 2020 — 193,164																	287,117,000
other — net of accumulated amortization — 2021 — 63,030 and 2020 — 56,943																	43,820,000
trade receivables — net of allowance for credit losses — 2021 — 5,652 and 2020 — 5,313																		153,443,000
developed technology — net of accumulated amortization —2021 — 213,621 and 2020 — 193,164																		297,471,000
other — net of accumulated amortization — 2021 — 60,993 and 2020 — 56,943																		45,321,000
trade receivables — net of allowance for credit losses — 2021 — 5,953 and 2020 — 5,313																			150,314,000
developed technology — net of accumulated amortization —2021 — 203,308 and 2020 — 193,164																			307,713,000
other — net of accumulated amortization — 2021 — 59,025 and 2020 — 56,943																			48,312,000
trade receivables — net of allowance for credit losses — 2020 — 5,313 and 2019 — 3,108																				146,641,000
developed technology — net of accumulated amortization —2020 — 193,164 and 2019 — 149,947																				318,059,000
other — net of accumulated amortization — 2020 — 56,943 and 2019 — 65,607																				49,856,000
assets
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,687 and 2019 — 3,108																					141,957,000
developed technology — net of accumulated amortization —2020 — 182,148 and 2019 — 149,947																					331,851,000
other — net of accumulated amortization — 2020 — 56,913 and 2019 — 65,607																					50,964,000
trade receivables — net of allowance for uncollectible accounts — 2020 — 3,866 and 2019 — 3,108																						138,792,000
developed technology — net of accumulated amortization —2020 — 174,495 and 2019 — 149,947																						354,273,000
other — net of accumulated amortization — 2020 — 59,926 and 2019 — 65,607																						59,717,000
trade receivables — net of allowance for uncollectible accounts — 2020 — 4,124 and 2019 — 3,108																							150,050,000
developed technology — net of accumulated amortization —2020 — 162,135 and 2019 — 149,947																							366,551,000
other — net of accumulated amortization — 2020 — 59,934 and 2019 — 65,607																							63,693,000
trade receivables — net of allowance for uncollectible accounts — 2019 — 3,108 and 2018 — 2,355																								155,365,000
developed technology — net of accumulated amortization —2019 — 149,947 and 2018 — 102,357																								379,529,000
other — net of accumulated amortization — 2019 — 65,607 and 2018 — 49,136																								65,783,000
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,848 and 2018 — 2,355																									144,683,000
developed technology — net of accumulated amortization —2019 — 137,551 and 2018 — 102,357																									390,796,000
other — net of accumulated amortization — 2019 — 62,378 and 2018 — 49,136																									68,111,000
total																									1,761,704,000	1,736,270,000	1,689,793,000					1,111,811,000			1,015,181,000			814,965,000														243,935,000	210,508,000	192,617,000	185,391,000	180,824,000		171,943,000	165,773,000	161,659,000	160,234,000	157,254,000	153,548,000		148,809,000	145,802,000	141,462,000		136,392,000	132,638,000	128,217,000	120,991,000	110,969,000	96,657,000	77,510,000	68,510,443
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,656 and 2018 — 2,355																										156,444,000
prepaid expenses and current other assets																										12,305,000	11,220,000
developed technology — net of accumulated amortization — 2019 — 125,447 and 2018 — 102,357																										391,651,000
other — net of accumulated amortization — 2019 — 56,289 and 2018 — 49,136																										74,419,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2019 and december 31, 2018
liabilities and stockholders’ equity																																																																						2,006,000
current liabilities:
trade payables																										52,601,000	51,680,000	15,726,000	15,936,000	15,767,000	8,409,000	34,931,000	-876,000	3,664,000	32,625,000	-6,835,000	-9,018,000	31,286,000	2,400,000	14,766,000	84,000	5,326,000	655,000	2,299,000	-485,000	-5,000	586,000	-2,084,000	7,721,000	5,805,000	-2,129,000						296,000	13,570,000	14,304,000	13,191,000		11,709,000	11,246,000		10,158,000	11,140,000	11,818,000	305,000	11,270,000	10,758,000	10,427,000	12,506,000	13,054,000	12,359,000	8,727,000	8,600,311
accrued expenses																										97,176,000	91,310,000	12,706,000	7,707,000	7,467,000	-2,395,000	58,932,000	4,514,000	7,833,000	52,875,000	3,245,000	1,693,000	40,196,000	-3,936,000	5,656,000	2,653,000	6,137,000	4,686,000	3,539,000	2,868,000	-276,000	-3,705,000	-2,280,000	4,448,000	2,793,000	1,334,000						1,628,000	13,213,000	12,182,000	11,553,000		10,856,000	9,821,000	872,000	9,880,000	9,794,000	8,684,000		8,827,000	9,853,000	8,549,000	9,121,000	8,651,000	7,667,000	7,385,000	7,884,561
current portion of long-term debt																										15,000,000	22,000,000					19,459,000			16,998,000			10,000,000																															1,000	1,000	1,000	2,000	4,000	5,000
short-term operating lease liabilities																										11,732,000
income taxes payable																										42,000	1,644,000	918,000	-1,528,000	-2,076,000	-480,000	2,298,000	-764,000	-301,000	2,120,000	1,451,000	-183,000	3,138,000	578,000	2,199,000	1,377,000	1,083,000	3,248,000	759,000	91,000	255,000	-1,319,000	-34,000	2,057,000	2,670,000	2,658,000						825,000	1,472,000	2,161,000	2,109,000		846,000	2,334,000	1,595,000	138,000	401,000	819,000	2,724,000	1,541,000	1,448,000	1,223,000	1,016,000	1,578,000	3,237,000	1,076,000	2,239,977
total current liabilities																										176,551,000	178,459,000					115,620,000			105,097,000			85,093,000																				35,660,000	36,075,000	27,167,000		25,252,000	25,162,000		20,487,000	21,647,000	21,553,000		22,662,000	23,053,000	20,995,000	23,645,000	24,064,000	23,863,000	17,335,000	18,932,946
long-term debt																										385,221,000	362,187,000					259,013,000			220,408,000			221,719,000																															3,000	3,000	4,000	3,000	5,000	5,000
deferred income tax liabilities																										60,932,000	56,324,000					23,289,000			20,482,000			11,024,000																				8,788,000	8,789,000	8,782,000		6,511,000	6,533,000		97,000	4,812,000	4,344,000		812,000	720,000	568,000	768,000	503,000	449,000	2,991,000	3,218,893
long-term income taxes payable																										392,000	392,000	-4,454,000				4,846,000
liabilities related to unrecognized tax benefits																										3,013,000	3,013,000	267,000				2,746,000			438,000	597,000	-366,000	768,000		536,000		-76,000	-844,000	-264,000		-520,000			-209,000	-993,000	-226,000
deferred compensation payable																										12,739,000	12,480,000	39,000	994,000	438,000	3,000	11,181,000	1,107,000	513,000	9,399,000	712,000	500,000	9,103,000	-305,000	-135,000	473,000	802,000	644,000	532,000	282,000	1,877,000	647,000	281,000	1,371,000	838,000	327,000						1,034,000	3,048,000	2,736,000	2,205,000		3,207,000	3,048,000		2,893,000	3,022,000	2,950,000		2,594,000	2,586,000	2,588,000	2,211,000	2,064,000	1,918,000	1,470,000	1,281,982
deferred credits																										2,192,000	2,227,000					2,403,000			2,510,000			2,635,000																				1,903,000	1,931,000	1,967,000		2,052,000	2,078,000		2,134,000	2,167,000	2,200,000		2,280,000	2,325,000	2,370,000	2,462,000	2,510,000	2,561,000	1,352,000	1,404,884
long-term operating lease liabilities																										71,272,000
other long-term obligations																										73,283,000	62,357,000	-801,000	-1,381,000	-179,000	-337,000	16,379,000	574,000	907,000	4,505,000	-200,000	-251,000	4,633,000	-76,000	1,769,000	433,000	566,000	764,000	446,000	-50,000	-4,399,000	-127,000	294,000	-89,000	314,000	-70,000							461,000	386,000	395,000		371,000			435,000	528,000
total liabilities																										785,595,000	749,682,000					435,477,000			362,839,000			334,975,000																				52,541,000	52,735,000	43,334,000		39,981,000	39,798,000		34,878,000	36,033,000	34,917,000		31,735,000	32,186,000	30,188,000	30,927,000	31,133,000	30,897,000	23,148,000	24,838,705
commitments and contingencies
stockholders’ equity:
preferred stock — 5,000 shares authorized as of june 30, 2019 and december 31, 2018; no shares issued
common stock																										579,250,000	574,946,000					353,392,000			344,497,000			200,015,000
retained earnings																										376,572,000	369,713,000					321,408,000			308,688,000			285,405,000																				150,137,000	144,052,000	138,211,000		122,082,000	116,264,000		107,220,000	102,925,000	99,329,000		93,916,000	90,591,000	87,069,000	80,974,000	77,647,000	72,965,000	64,594,000	60,405,915
accumulated other comprehensive loss																										-5,147,000	-4,548,000								-843,000			-5,430,000
total stockholders’ equity																										950,675,000	940,111,000					676,334,000			652,342,000			479,990,000																				212,090,000	204,330,000	197,816,000		177,454,000	170,961,000		158,287,000	154,563,000	154,526,000		145,372,000	140,534,000	135,886,000	128,054,000	122,284,000	115,443,000	105,846,000	100,659,694
trade receivables — net of allowance for uncollectible accounts — 2019 — 2,406 and 2018 — 2,355																											146,488,000
developed technology — net of accumulated amortization — 2019 — 113,765 and 2018 — 102,357																											371,603,000
other — net of accumulated amortization — 2019 — 52,469 and 2018 — 49,136																											77,104,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2019 and december 31, 2018
short-term operating lease liability																											11,825,000
long-term operating lease liability																											72,243,000
preferred stock — 5,000 shares authorized as of march 31, 2019 and december 31, 2018; no shares issued
cash flows from operating activities:
net income																												42,017,000	32,828,000	16,210,000	5,269,000		20,717,000	24,286,000		20,121,000	12,615,000		4,351,000	23,802,000	5,174,000	22,974,000	14,303,000	6,539,000	2,823,000	16,570,000	4,423,000	671,000	19,710,000	19,069,000	23,044,000						22,530,000							15,588,000				12,301,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization																												69,546,000	50,436,000	32,779,000	15,284,000		39,388,000	25,709,000		43,755,000	31,594,000		9,705,000	37,425,000	9,068,000	35,929,000	26,719,000	17,593,000	8,702,000	32,542,000	15,729,000	7,683,000	22,534,000	16,724,000	19,194,000						12,271,000							9,444,000				8,275,000
gain on bargain purchase																																	-10,796,000	-11,574,000
losses on sales and/or abandonment of property and equipment																												625,000					219,000	234,000			102,000		29,000		37,000	916,000	549,000		91,000	177,000			204,000		31,000						271,000							317,000				242,000
write-off of patents and intangible assets																												814,000	744,000	86,000	57,000		86,000	19,000		101,000	90,000			141,000	14,000	1,427,000	1,360,000		34,000	8,208,000
acquired in-process research and development																												644,000	382,000	306,000			12,136,000	75,000		461,000	400,000			1,000,000									2,450,000	2,450,000	5,838,000
amortization of deferred credits																												-142,000	-106,000	-71,000	-36,000		-111,000	-76,000		-170,000	-128,000		-43,000	-171,000	-43,000	-175,000	-131,000	-88,000	-45,000	-139,000	-64,000	-32,000	-174,000	-140,000	-106,000
amortization of long-term debt issuance costs																												804,000	603,000	402,000	201,000		514,000	343,000		952,000	779,000		257,000	987,000	247,000	987,000	741,000	494,000	247,000	845,000	399,000	199,000
deferred income taxes																												2,052,000					-290,000	-295,000		-962,000	187,000		170,000	3,450,000	462,000	3,870,000	-184,000	19,000	21,000	1,359,000	-6,000	2,000	549,000	14,000	1,677,000						1,791,000							984,000				376,000
excess tax benefits from stock-based compensation																																				-669,000	-527,000		3,000	-2,124,000	-860,000	-576,000	-243,000	-236,000	-168,000	-259,000	-124,000	53,000	-877,000	716,000	3,122,000
stock-based compensation expense																												6,117,000	4,494,000	2,821,000	1,256,000		2,883,000	1,691,000		2,506,000	1,913,000		624,000	2,243,000	520,000	1,460,000	1,004,000	663,000	339,000	1,467,000	783,000	459,000	1,917,000	1,454,000	1,644,000						1,182,000
changes in operating assets and liabilities, net of effects from acquisitions:
trade receivables																												-27,522,000	-25,482,000	-27,947,000	-13,166,000		-10,963,000	-13,248,000		-6,816,000	-5,166,000		-835,000	-5,872,000	-2,334,000	-13,599,000	-9,198,000	-7,152,000	-4,115,000	-6,445,000	-5,190,000	-1,473,000	-6,576,000	-7,521,000	-3,323,000																	57,000
total adjustments																												44,516,000	30,029,000	18,839,000	2,666,000		22,676,000	10,280,000		33,478,000	23,723,000		7,232,000	45,656,000	14,098,000	30,351,000	17,282,000	13,600,000	5,137,000	34,803,000	9,942,000	2,222,000	27,228,000	13,093,000	10,971,000						7,540,000							16,531,000				6,805,000
net cash from operating activities																												86,533,000	62,857,000	35,049,000	7,935,000		43,393,000	34,566,000		53,599,000	36,338,000		11,583,000	69,458,000	19,272,000	53,325,000	31,585,000	20,139,000	7,960,000	51,373,000	14,365,000	2,893,000	46,938,000	32,162,000	34,015,000						30,070,000							32,119,000				19,106,000
cash flows from investing activities:
capital expenditures for:
property and equipment																												-63,324,000	-47,024,000	-31,559,000	-16,239,000		-29,522,000	-17,782,000		-32,837,000	-26,492,000		-10,991,000	-50,959,000	-9,492,000	-34,181,000	-24,262,000	-18,716,000	-8,708,000	-59,505,000	-30,389,000	-19,961,000	-64,643,000	-49,264,000	-59,195,000
intangible assets																												-3,012,000	-2,234,000	-1,755,000	-885,000		-1,927,000	-1,082,000		-2,217,000	-1,594,000		-482,000	-1,956,000	-495,000	-1,714,000	-1,368,000	-925,000	-433,000	-1,617,000			-1,460,000
proceeds from sale of cost method investment																																				1,089,000	1,089,000		1,089,000
proceeds from the sale of property and equipment																												55,000	7,000	4,000	3,000		9,000	3,000		19,000	5,000			1,247,000	3,000	98,000	62,000	21,000	18,000	113,000	53,000	8,000	43,000	9,000	5,000						27,000							11,000				27,000
issuance of notes receivable																												-10,750,000
cash paid in acquisitions, net of cash acquired																												-301,789,000	-122,770,000	-118,654,000	-100,195,000		-103,500,000	-54,809,000		-125,161,000	-119,808,000		-21,500,000	-12,368,000	-1,250,000	-5,927,000	-4,202,000	-1,450,000		-31,600,000			-192,762,000		-10,250,000
net cash from investing activities																												-378,820,000	-182,771,000	-162,464,000	-117,316,000		-134,940,000	-73,670,000		-159,107,000	-146,800,000		-31,884,000	-62,019,000	-9,411,000	-36,203,000	-26,586,000	-21,070,000	-9,123,000	-68,609,000	-31,997,000	-21,347,000	-255,574,000	-70,621,000	-74,020,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2018, 2017 and 2016
cash flows from financing activities:
proceeds from issuance of common stock																												214,993,000	213,276,000	3,251,000	1,511,000		143,069,000	140,989,000		5,271,000	4,422,000		557,000	6,668,000	4,021,000	8,146,000	3,811,000	3,528,000	803,000	3,729,000	876,000	571,000	3,755,000	3,326,000	95,454,000
offering costs																												-366,000	-366,000
proceeds from issuance of long-term debt																												639,108,000	380,825,000	320,827,000	256,971,000		151,462,000	96,859,000		219,505,000	203,478,000		55,184,000	152,375,000	31,803,000	144,018,000	108,782,000	71,734,000	36,010,000	176,764,000			330,630,000		104,585,000
payments on long-term debt																												-522,608,000	-450,575,000	-185,827,000	-148,971,000		-197,962,000	-179,359,000		-102,098,000	-82,658,000		-34,376,000	-169,272,000	-43,415,000	-169,392,000	-117,772,000	-72,213,000	-30,423,000	-165,477,000	-51,910,000	-17,512,000	-123,801,000	-94,151,000	-155,386,000
long-term debt issuance costs																																				-1,948,000	-1,948,000									-798,000			-3,706,000
contingent payments related to acquisitions																												-231,000	-184,000	-130,000	-15,000		-45,000	-30,000		-218,000	-199,000		-167,000	-1,212,000	-166,000	-67,000	-55,000	-38,000	-24,000	-77,000	-38,000	-19,000	-57,000	-36,000
payment of taxes related to an exchange of common stock																												-2,616,000	-2,616,000							-86,000	-86,000			-918,000	-380,000	-249,000	-220,000	-220,000	-220,000	-21,000	-21,000		-439,000	-287,000	-953,000
net cash from financing activities																												328,280,000	140,360,000	138,121,000	109,496,000		95,708,000	57,644,000		121,095,000	123,536,000		21,195,000	-10,235,000	-7,277,000	-16,968,000	-5,211,000	3,027,000	6,314,000	14,768,000	20,953,000	18,042,000	208,288,000	37,806,000	46,695,000
effect of exchange rates on cash																												-970,000	-827,000	470,000	1,720,000		30,000	-36,000		-593,000	67,000		91,000	-382,000	-31,000	-258,000	-809,000	-154,000	-19,000	208,000	103,000	-290,000	-61,000	-10,000	-297,000
net increase in cash and cash equivalents																												35,023,000	19,619,000	11,176,000	1,835,000		4,191,000	18,504,000		14,994,000	13,141,000		985,000		2,553,000			1,942,000	5,132,000	-2,260,000	3,424,000		-409,000	-663,000	6,393,000
cash and cash equivalents:
beginning of year																												32,336,000								4,177,000				7,355,000		7,459,000				9,719,000			10,128,000		3,735,000
end of year																												67,359,000								19,171,000				4,177,000		7,355,000				7,459,000			9,719,000		10,128,000
supplemental disclosures of cash flow information
cash paid during the year for:
interest																												10,324,000	8,018,000	5,714,000	2,383,000		5,953,000	4,386,000		8,872,000	6,223,000		1,378,000	6,273,000	1,254,000	9,014,000	7,204,000	4,969,000	2,644,000	7,877,000	2,970,000	1,493,000	434,000	238,000	509,000
income taxes																												8,692,000	6,069,000	5,141,000	1,810,000		4,029,000	2,678,000		2,318,000	2,237,000		428,000	3,409,000	931,000	3,289,000	2,679,000	1,911,000	782,000	735,000	1,071,000	403,000	5,277,000	4,629,000	7,023,000
supplemental disclosures of non-cash investing and financing activities
property and equipment purchases in accounts payable																												4,989,000	3,058,000	3,943,000	1,752,000		1,394,000	1,560,000		2,398,000	2,709,000		1,584,000	3,199,000	1,743,000	2,896,000	3,853,000	3,433,000	5,180,000	4,055,000	12,372,000	5,354,000	12,372,000	7,429,000	8,849,000
contingent receivable in exchange for sale of equity investment
receivable for issuance of common stock associated with option exercises
acquisition purchases in accrued expenses and other long-term obligations																												72,209,000					12,000,000	6,000,000			293,000			1,300,000		1,000,000				350,000			5,149,000	5,000,000
merit common stock surrendered (43, 0 and 14 shares, respectively) in exchange for exercise of stock options																												2,261,000
loss on sales and/or abandonment of property and equipment																													425,000	371,000	351,000																	7,000
issuance of note receivable																													-10,750,000	-10,500,000
merit medical systems, inc. and subsidiaries
consolidated statements of cash flows
for the nine months ended september 30, 2018 and 2017
beginning of period																													32,336,000	32,336,000	32,336,000		19,171,000	19,171,000			4,177,000		4,177,000		7,355,000		7,459,000	7,459,000	7,459,000		9,719,000	9,719,000		10,128,000
end of period																													51,955,000	43,512,000	34,171,000		23,362,000	37,675,000			17,318,000		5,162,000		9,908,000		6,438,000	9,401,000	12,591,000		13,143,000	9,017,000		9,465,000
cash paid during the period for:
merit common stock surrendered (43 and 0 shares, respectively) in exchange for exercise of stock options																													2,262,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2018 and 2017
merit common stock surrendered (32 and 0 shares, respectively) in exchange for exercise of stock options																														1,684,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2018 and 2017
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,769 and 2016 — 1,587																																105,536,000
prepaid expenses and other assets																																9,096,000	-1,587,000	-1,230,000	7,778,000																	4,302,000	3,988,000	2,946,000	3,047,000	2,238,000		1,832,000	1,959,000	1,184,000	1,482,000	1,655,000	1,072,000		1,463,000	1,702,000	1,241,000	6,000	1,568,000	1,695,000	1,086,000	1,278,000	1,243,000	741,000	1,071,000	1,082,323
developed technology — net of accumulated amortization — 2017 — 72,420 and 2016 — 52,843																																167,771,000
other — net of accumulated amortization — 2017 — 38,127 and 2016 — 30,048																																59,553,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsdecember 31, 2017 and 2016
preferred stock — 5,000 shares authorized as of december 31, 2017 and 2016; no shares issued
accumulated other comprehensive income																																1,534,000																														100,000	133,000
fair value changes in contingent liabilities/assets																																					99,000
employee receivables																																	54,000	54,000	161,000	15,000	42,000	165,000	-43,000	-52,000	-6,000	46,000	44,000	44,000	35,000	-53,000	-27,000	-18,000	-11,000	-78,000	-62,000	199,000	161,000	133,000	145,000	129,000		171,000	139,000	115,000	118,000	130,000	161,000	52,000	119,000	133,000	183,000		164,000	160,000	116,000	143,000	114,000
advances from employees																																	-44,000	-412,000	479,000	-3,000	-50,000	473,000	-388,000	217,000	439,000	142,000	599,000	371,000	509,000	-277,000	142,000	90,000	317,000	408,000	-65,000							405,000	428,000	314,000		341,000	261,000	11,000	214,000	312,000	232,000		211,000	273,000	227,000	232,000	274,000	146,000	132,000	208,097
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2017 and 2016
payment of offering costs related to issuance of common stock																																	-816,000	-815,000																	-127,000
contingent receivable in exchange for sale of cost method investment																																				711,000
merit common stock surrendered (0 and 14 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2017 and 2016
trade receivables — net of allowance for uncollectible accounts — 2017 — 1,437 and 2016 — 1,587																																			95,252,000
developed technology — net of accumulated amortization — 2017 — 57,373 and 2016 — 52,843																																			156,414,000
other — net of accumulated amortization — 2017 — 31,459 and 2016 — 30,048																																			52,176,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsmarch 31, 2017 and december 31, 2016
preferred stock — 5,000 shares authorized as of march 31, 2017 and december 31, 2016; no shares issued
losses (gains) on sales and/or abandonment of property and equipment																																				530,000				-23,000				289,000
prepaid expenses																																				271,000	-452,000	7,829,000	-498,000	-696,000	-160,000	-58,000	-608,000	-366,000	-651,000	-758,000	-669,000	-1,242,000	736,000	-598,000	-1,726,000
proceeds from sale-leaseback transactions																																								2,017,000	1,823,000	5,521,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2016, 2015 and 2014
receivable due for sale of equipment																																										1,256,000
cost method investment converted to intangible asset in acquisition in lieu of additional cash payment																																								1,010,000
merit common stock surrendered (14, 185 and 127 shares, respectively) in exchange for exercise of stock options																																				346,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2016 and 2015
supplemental disclosure of non-cash investing and financing activities
contingent receivable received in exchange for sale of cost method investment																																					711,000		681,000
merit common stock surrendered (14 and 185 shares, respectively) in exchange for exercise of stock options																																					346,000
trade receivables — net of allowance for uncollectible accounts — 2016 — 1,498 and 2015 — 1,297																																						76,792,000
developed technology — net of accumulated amortization — 2016 — 44,401 and 2015 — 38,497																																						76,111,000
other — net of accumulated amortization — 2016 — 28,569 and 2015 — 26,603																																						40,587,000
merit medical systems, inc. and subsidiariesconsolidated balance sheetsjune 30, 2016 and december 31, 2015
preferred stock — 5,000 shares authorized as of june 30, 2016 and december 31, 2015; no shares issued
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2016 and 2015
merit common stock surrendered (0 and 89 shares, respectively) in exchange for exercise of stock options
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2015, 2014 and 2013
proceeds from industrial assistant grants																																														389,000	750,000	750,000	1,029,000	324,000
net decrease in cash and cash equivalents																																								-3,178,000			-1,021,000					-702,000
merit common stock surrendered (185, 127 and 45 shares, respectively) in exchange for exercise of stock options																																								3,802,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2015 and 2014
merit common stock surrendered (89 and 108 shares, respectively) in exchange for exercise of stock options																																									1,725,000
impairment of cost-method investment																																																	2,368,000
realized gain on sale of marketable securities																																																	-745,000	-745,000
proceeds from the sale of marketable securities																																																	3,248,000	3,248,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2014, 2013 and 2012
net (decrease) in cash and cash equivalents																																										-104,000
acquisition of customer list in exchange for a settlement of trade receivables																																																	377,000	378,000
merit common stock surrendered (127, 45 and 131 shares, respectively) in exchange for exercise of stock options																																										1,941,000
proceeds from sale-leaseback transaction																																											3,184,000			24,000,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2014 and 2013
merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options																																											1,641,000	1,641,000
write-off of patents																																												119,000			53,000	2,000		27,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2014 and 2013
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2014 and 2013
merit common stock surrendered (108 and 0 shares, respectively) in exchange for exercise of stock options																																													1,641,000
purchase of marketable securities																																																			-2,503,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2013, 2012 and 2011
merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options																																														452,000
gain on sales and/or abandonment of property and equipment																																															-10,000
changes in fair value of contingent consideration liability related to acquisitions																																																		370,000
income tax refund receivable																																															1,073,000	-782,000	452,000	259,000	-733,000						319,000																			28,227
patents and trademarks																																															-661,000	-394,000		-1,059,000	-2,077,000
cash paid in acquisitions																																															-1,000,000	-1,000,000		-23,555,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the six months ended june 30, 2013 and 2012
borrowings under long-term debt																																															71,172,000	34,199,000		127,914,000
supplemental disclosures of cash flow information —
supplemental disclosures of non-cash investing and financing activities:
merit common stock surrendered (45 and 103 shares, respectively) in exchange for exercise of stock options																																															452,000
excess tax benefit from stock-based compensation																																																-53,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the three months ended march 31, 2013 and 2012
write-off of patents and license agreement																																																	55,000		103,000
goodwill impairment charge
purchase of trading investments
unrealized gains on trading investments
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2012, 2011 and 2010
borrowings on line of credit
payments on line of credit
merit common stock surrendered (131, 78 and 0 shares, respectively) in exchange for exercise of stock options																																																	1,831,000
(gain) loss on sales and/or abandonment of property and equipment																																																		-1,000
tax benefit attributable to appreciation of common stock options exercised																																																		-716,000	-3,122,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsfor the nine months ended september 30, 2012 and 2011
merit common stock surrendered (71 and 103 shares, respectively) in exchange for exercise of stock options																																																		1,032,000
merit medical systems, inc. and subsidiariesconsolidated statements of cash flowsyears ended december 31, 2011, 2010 and 2009
common stock repurchased and retired
acquisition purchases in other long term obligations																																																			1,270,000
merit common stock surrendered (78, 0 and 27 shares, respectively) in exchange for exercise of stock options																																																			1,252,000
trade receivables - net of allowances of 473 and 593, respectively																																																				40,579,000
income tax refunds receivable																																																				467,000	472,000	428,000	177,000	267,000		667,000	651,000	626,000	1,108,000	350,000	418,000		105,000	188,000	81,000		19,000	46,000	22,000
building																																																				51,072,000	50,399,000	50,137,000	49,768,000	50,295,000		50,000,000	49,903,000	49,865,000	49,406,000	49,125,000	43,241,000		43,111,000	43,059,000	43,037,000		42,557,000	42,533,000	42,487,000	39,583,000	23,702,000	18,840,000	5,950,000	5,269,821
property and equipment—net																																																				162,523,000	135,582,000	122,474,000	118,072,000	116,212,000		111,194,000	107,513,000	105,748,000	103,724,000	102,595,000	100,735,000		98,288,000	97,697,000	95,421,000		91,811,000	89,987,000	86,834,000	82,990,000	74,385,000	61,227,000	44,344,000	36,432,768
intangibles - net of accumulated amortization of 13,498 and 8,996, respectively																																																				58,544,000
trade receivables - net of allowances of 492 and 593, respectively																																																					41,031,000
intangibles - net of accumulated amortization of 10,573 and 8,996, respectively																																																					56,828,000
trade receivables - net of allowances of 660 and 541, respectively																																																						38,644,000
other intangibles - net of accumulated amortization of 7,754 and 5,450, respectively																																																						59,796,000
trade receivables - net of allowances of 599 and 541, respectively																																																							37,010,000
other intangibles - net of accumulated amortization of 6,782 and 5,450, respectively																																																							26,958,000
trade receivables - net of allowances of 487 and 541, respectively																																																								34,770,000
intangibles - net of accumulated amortization of 6,120 and 5,450, respectively																																																								27,294,000
write-off of certain patents and license agreement																																																									154,000
proceeds from sale of trading investments
unrealized (gains) losses on trading investments
changes in operating assets and liabilities net of effects from acquisitions:
current liabilities related to unrecognized tax positions																																																																1,023,000
non-current liabilities related to unrecognized tax positions																																																									114,000
trade receivables - net of allowances of 650 and 505, respectively																																																										31,812,000
other intangibles - net of accumulated amortization of 4,720 and 3,122, respectively																																																										25,899,000
deposits																																																										92,000	91,000	126,000	73,000	78,000	78,000	12,000	84,000	84,000	84,000	9,000	96,000	99,000	99,000	128,000	156,000	137,000	127,000	126,874
other payables																																																										7,000,000	7,000,000			1,500,000	1,500,000
liabilities related to unrecognized tax positions																																																										2,681,000	2,818,000	2,818,000		2,588,000	2,588,000		3,388,000	3,857,000	3,692,000
preferred stock—5,000 shares authorized as of september 30, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 28,059 and 28,093 shares issued at september 30, 2009 and december 31, 2008, respectively																																																										62,012,000
total liabilities and stockholders’ equity																																																										264,631,000	257,065,000	241,150,000		217,435,000	210,759,000		193,165,000	190,596,000	189,443,000		177,107,000	172,720,000	166,074,000	158,981,000	153,417,000	146,340,000	128,994,000	125,498,399
trade receivables - net of allowances of 621 and 505, respectively																																																											30,454,000
other intangibles - net of accumulated amortization of 3,986 and 3,122, respectively																																																											26,503,000
preferred stock—5,000 shares authorized as of june 30, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 27,943 and 28,093 shares issued at june 30, 2009 and december 31 2008, respectively																																																											60,343,000
trade receivables - net of allowances of 636 and 505, respectively																																																												29,794,000
other intangibles - net of accumulated amortization of 3,421 and 3,122, respectively																																																												17,344,000
preferred stock—5,000 shares authorized as of march 31, 2009 and december 31, 2008; no shares issued
common stock—no par value; 100,000 shares authorized; 27,916 and 28,093 shares issued at march 31, 2009 and december 31 2008, respectively																																																												59,732,000
marketable securities																																																													894,000
trade receivables - net of allowances of 460 and 497, respectively																																																													26,330,000
less accumulated depreciation and amortization
other intangibles - net of accumulated amortization of 2,891 and 2,171, respectively																																																													6,998,000
deferred compensation investments																																																													2,910,000
trade receivables - net of allowances of 515 and 497, respectively																																																														25,212,000
other intangibles - net of accumulated amortization of 2,671 and 2,171, respectively																																																														6,429,000
deferred compensation assets																																																														3,053,000
preferred stock—5,000 shares authorized as of june 30, 2008, no shares issued
common stock—no par value; 50,000 shares authorized; 27,635 and 27,413 shares issued at june 30, 2008 and december 31 2007, respectively																																																														55,272,000
trade receivables - net of allowances of 511 and 497, respectively																																																															25,391,000
other intangibles - net of accumulated amortization of 2,396 and 2,171, respectively																																																															6,610,000
other long-term obligation																																																															389,000				178,000		62,000	75,000	87,000
preferred stock—5,000 shares authorized as of march 31, 2008, no shares issued
common stock—no par value; 50,000 shares authorized; 27,589 and 27,413 shares issued at march 31, 2008 and december 31 2007, respectively																																																															54,564,000
impairment of assets																																																																				929,000
write-off of certain patents and trademarks																																																																245,000				40,000
stock-based compensation																																																																1,130,000				1,502,000
other long-term assets
increase in cash surrender value of life insurance contracts
cash paid in acquisitions—net of cash acquired
trade receivables - less allowances of 530 and 560, respectively																																																																	24,844,000
other intangibles - less accumulated amortization of 2,085 and 1,519, respectively																																																																	6,438,000
preferred stock—5,000 shares authorized as of september 30, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,304 and 27,647 shares issued at september 30, 2007 and december 31, 2006, respectively																																																																	51,088,000
trade receivables - less allowances of 518 and 560, respectively																																																																		25,029,000
other intangibles - less accumulated amortization of 1,897 and 1,519, respectively																																																																		5,369,000
preferred stock—5,000 shares authorized as of june 30, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,383 and 27,647 shares issued at june 30, 2007 and december 31, 2006, respectively																																																																		51,755,000
trade receivables - less allowances of 544 and 560, respectively																																																																			25,986,000
other intangibles - less accumulated amortization of 1,687 and 1,519, respectively																																																																			4,705,000
preferred stock—5,000 shares authorized as of march 31, 2007, no shares issued
common stock—no par value; 50,000 shares authorized; 27,711 and 27,647 shares issued at march 31, 2007 and december 31 2006, respectively																																																																			55,336,000
note receivable
trade receivables - less allowances of 498 and 767, respectively																																																																					23,317,000
other intangibles - less accumulated amortization of 1,824 and 1,483, respectively																																																																					4,298,000
preferred stock—5,000 shares authorized as of september 30, 2006, no shares issued
common stock—no par value; 50,000 shares authorized; 27,399 and 27,163 shares issued at september 30, 2006 and december 31 2005, respectively																																																																					51,707,000
trade receivables - less allowances of 442 and 767, respectively																																																																						23,150,000
other intangibles - less accumulated amortization of 1,634																																																																						3,595,000
and 1,483, respectively
preferred stock—5,000 shares authorized as of
june 30, 2006, no shares issued
common stock—no par value; 50,000 shares
authorized; 27,308 and 27,163 shares issued
at june 30, 2006 and december 31 2005, respectively																																																																						50,179,000
trade receivables - less allowances of 400 and 767, respectively																																																																							22,672,000
other intangibles - less accumulated amortization of 1,580 and 1,483, respectively																																																																							3,320,000
preferred stock—5,000 shares authorized as of march 31, 2006, no shares issued
common stock—no par value; 50,000 shares authorized; 27,217 and 27,163 shares issued at march 31, 2006 and december 31 2005, respectively																																																																							49,163,000
trade receivables - net																																																																								21,705,000	21,199,000		17,215,000	19,918,295
other intangibles																																																																								2,747,000	2,758,000
other liabilities																																																																								112,000	125,000	138,000
preferred stock—5,000 shares authorized as of september 30, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 27,128 and 26,486 shares issued at september 30, 2005 and december 31 2004, respectively																																																																								47,469,000
preferred stock—5,000 shares authorized as of june 30, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 26,895 and 26,486 shares issued at june 30, 2005 and december 31 2004, respectively																																																																									45,027,000
trade receivables - less allowances of 735 and 758, respectively																																																																										20,544,000
employee and other receivables																																																																										203,000	157,000	339,287
other intangibles - less accumulated amortization of 1,358 and 1,332, respectively																																																																										2,767,000
preferred stock—5,000 shares authorized as of march 31, 2005, no shares issued
common stock—no par value; 50,000 shares authorized; 26,515 and 26,486 shares issued at march 31, 2005 and december 31 2004, respectively																																																																										42,887,000
land																																																																											2,740,000	2,740,394
automobiles																																																																											88,000	87,536
patents, trademarks and licenses - net																																																																											1,942,000	2,106,451
deferred taxes payable																																																																											15,000
preferred stock—5,000 shares authorized as of june 30, 2004, no shares issued
common stock—no par value; 50,000 shares authorized; 26,429 and 26,003 shares issued at september 30, 2004 and december 31 2003, respectively																																																																											41,676,000
preferred stock—5,000,000 shares authorized as of june 30, 2004, no shares issued
common stock—no par value; 50,000,000 shares authorized; 26,334,864 and 26,002,544 shares issued at june 30, 2004 and december 31 2003, respectively																																																																												40,678,352
total liabilities and stockholders' equity

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.